NEW YORK, Aug. 30 – Lion Bioscience of Heidelberg, Germany, said Thursday that it had licensed its SRS platform to Genomics Collaborative of Cambridge, Mass.
The companies said the SRS platform would allow users to access GCI's databases of patient clinical and sample information as well as public biological data sources via one portal.
"Using SRS we are now able to look at cross sections of our data within a distributed environment using only one system,” Brent Richter, GCI's director of bioinformatics, said in a statement.
“This effort used to require two to three different tools which had limited user access,” Richter added.
Genomics Collaborative performs disease association studies, target validation, and tissue-based studies to develop pharmaceutical and pharmacogenomic products.
The company recently signed up its first five biopharmaceutical companies for subscriptions to its Access database of DNA, sera, and tissue samples.
Lion's SRS system integrates more than 400 diverse databases, according to the company. The company's customers include Affymetrix and Celera, where it is used as a web portal for its Discovery System.
Financial terms of the license were not disclosed.